OncView™ Podcast: EGFR Exon 20 Insertion as a Therapeutic Target in NSCLC
In an OncView™ program, Zofia Piotrowska, MD, touched on testing, treatment approaches, and therapeutic options for EGFR exon 20 insertion mutations in non–small cell lung cancer.
As part of its OncView™ video series, CancerNetwork® spoke with Zofia Piotrowska, MD, an assistant professor of medicine at Harvard Medical School and a medical oncologist at Massachusetts General Hospital, about recent data and review updates in the treatment landscape for patients with metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations.
In the video series, Piotrowska discussed the following:
- Overview of Advanced NSCLC with EGFR Mutations Including Exon 20 Insertions
- Testing for the EGFR Exon 20 Insertion
- Historical Treatment Approach for EGFR Exon 20 Insertions in NSCLC
- Amivantamab for the Treatment of EGFR Exon 20 Insertions in NSCLC
- Mobocertinib for the Treatment of EGFR Exon 20 Insertions in NSCLC
- Treatment Selection for Patients With EGFR Exon 20 Insertions in NSCLC
- Unmet Needs and Future Directions
To watch more videos in the CancerNetwork® OncView™ series, visit cancernetwork.com/oncview.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
